Alliance for Regenerative Medicine (ARM) Neuralstem Presentation

Alliance for Regenerative Medicine (ARM) Neuralstem Presentation
April 17, 2018
Neuralstem is a clinical-stage biopharmaceutical company developing novel treatments for nervous system diseases of high unmet medical need. The company’s lead asset and stem cell therapy candidate, NSI-566, is a spinal cord-derived neural stem cell line being tested in Amyotrophic Lateral Sclerosis (ALS), chronic spinal cord injury (cSCI) and ischemic stroke. Additionally, NSI-189, is a chemical entity in development for major depressive disorder (MDD) and for Angelman syndrome, irradiation-induced cognitive impairment, neuropathy associated with Type 1 and Type 2 diabetes and stroke. These product candidates are based on the company’s proprietary neural stem cell technology.

Karl Johe, Ph.D., Chief Scientific Officer
Germantown, MD

This entry was posted in Chronic Spinal Cord Injury Research, Regenerative Medicine, spinal cord injury research, Stem Cell Research and tagged , . Bookmark the permalink.